{"id":1283,"date":"2023-12-23T06:25:43","date_gmt":"2023-12-23T06:25:43","guid":{"rendered":"https:\/\/o-force.info\/?p=1283"},"modified":"2025-02-02T11:02:25","modified_gmt":"2025-02-02T11:02:25","slug":"researech4","status":"publish","type":"post","link":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/","title":{"rendered":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?"},"content":{"rendered":"\n<p class=\"has-large-font-size wp-block-paragraph\">The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental treatment for AD beyond lecanemab, as shown in the table below.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-1024x576.jpg\" alt=\"\" class=\"wp-image-1352\" srcset=\"https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-1024x576.jpg 1024w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-300x169.jpg 300w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-768x432.jpg 768w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4-320x180.jpg 320w, https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4.jpg 1280w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The short peptide we are developing (JAL-TA9) is expected to be used as a safe and inexpensive fundamental tre [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"sns_share_botton_hide":"true","vkExUnit_sns_title":"","_vk_print_noindex":"","sitemap_hide":"","_veu_custom_css":"","veu_display_promotion_alert":"common","vkexunit_cta_each_option":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-1283","post","type-post","status-publish","format-standard","hentry","category-alzheimer"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"The short peptide we are developing (JAL-TA9) is expect\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"ja_JP\" \/>\n\t\t<meta property=\"og:site_name\" content=\"O-Force Co., Ltd - \u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3092\u76ee\u6307\u3059\u4f1a\u793e\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer&#039;s disease; will O-Force&#039;s short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd\" \/>\n\t\t<meta property=\"og:description\" content=\"The short peptide we are developing (JAL-TA9) is expect\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-12-23T06:25:43+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-02-02T11:02:25+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary\" \/>\n\t\t<meta name=\"twitter:title\" content=\"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer&#039;s disease; will O-Force&#039;s short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd\" \/>\n\t\t<meta name=\"twitter:description\" content=\"The short peptide we are developing (JAL-TA9) is expect\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#blogposting\",\"name\":\"9\\\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd\",\"headline\":\"9\\\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?\",\"author\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/author\\\/3d94259663e4aa3a8a6ec49c5878263511996f44\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/#person\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/o-force.info\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/Lecanemab-4.jpg\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#articleImage\",\"width\":1280,\"height\":720},\"datePublished\":\"2023-12-23T06:25:43+00:00\",\"dateModified\":\"2025-02-02T11:02:25+00:00\",\"inLanguage\":\"ja\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#webpage\"},\"articleSection\":\"Alzheimer, English, pll_65867d6854c6c\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info#listItem\",\"position\":1,\"name\":\"\\u30db\\u30fc\\u30e0\",\"item\":\"https:\\\/\\\/o-force.info\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/category\\\/alzheimer\\\/#listItem\",\"name\":\"Alzheimer\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/category\\\/alzheimer\\\/#listItem\",\"position\":2,\"name\":\"Alzheimer\",\"item\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/category\\\/alzheimer\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#listItem\",\"name\":\"9\\\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info#listItem\",\"name\":\"\\u30db\\u30fc\\u30e0\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#listItem\",\"position\":3,\"name\":\"9\\\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/category\\\/alzheimer\\\/#listItem\",\"name\":\"Alzheimer\"}}]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/author\\\/3d94259663e4aa3a8a6ec49c5878263511996f44\\\/#author\",\"url\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/author\\\/3d94259663e4aa3a8a6ec49c5878263511996f44\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d951f253ec39500cd05ce5b251166e5f9ad4df75285b9277068441bbf1fb7b2?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#webpage\",\"url\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/\",\"name\":\"9\\\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd\",\"description\":\"The short peptide we are developing (JAL-TA9) is expect\",\"inLanguage\":\"ja\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/en\\\/2023\\\/12\\\/23\\\/researech4\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/author\\\/3d94259663e4aa3a8a6ec49c5878263511996f44\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/index.php\\\/author\\\/3d94259663e4aa3a8a6ec49c5878263511996f44\\\/#author\"},\"datePublished\":\"2023-12-23T06:25:43+00:00\",\"dateModified\":\"2025-02-02T11:02:25+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/o-force.info\\\/#website\",\"url\":\"https:\\\/\\\/o-force.info\\\/\",\"name\":\"O-Force Co., Ltd\",\"description\":\"\\u30a2\\u30eb\\u30c4\\u30cf\\u30a4\\u30de\\u30fc\\u75c5\\u6cbb\\u7642\\u85ac\\u306e\\u958b\\u767a\\u3092\\u76ee\\u6307\\u3059\\u4f1a\\u793e\",\"inLanguage\":\"ja\",\"publisher\":{\"@id\":\"https:\\\/\\\/o-force.info\\\/#person\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd","description":"The short peptide we are developing (JAL-TA9) is expect","canonical_url":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#blogposting","name":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd","headline":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?","author":{"@id":"https:\/\/o-force.info\/index.php\/author\/3d94259663e4aa3a8a6ec49c5878263511996f44\/#author"},"publisher":{"@id":"https:\/\/o-force.info\/#person"},"image":{"@type":"ImageObject","url":"https:\/\/o-force.info\/wp-content\/uploads\/2023\/12\/Lecanemab-4.jpg","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#articleImage","width":1280,"height":720},"datePublished":"2023-12-23T06:25:43+00:00","dateModified":"2025-02-02T11:02:25+00:00","inLanguage":"ja","mainEntityOfPage":{"@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#webpage"},"isPartOf":{"@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#webpage"},"articleSection":"Alzheimer, English, pll_65867d6854c6c"},{"@type":"BreadcrumbList","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/o-force.info#listItem","position":1,"name":"\u30db\u30fc\u30e0","item":"https:\/\/o-force.info","nextItem":{"@type":"ListItem","@id":"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/#listItem","name":"Alzheimer"}},{"@type":"ListItem","@id":"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/#listItem","position":2,"name":"Alzheimer","item":"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/","nextItem":{"@type":"ListItem","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#listItem","name":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?"},"previousItem":{"@type":"ListItem","@id":"https:\/\/o-force.info#listItem","name":"\u30db\u30fc\u30e0"}},{"@type":"ListItem","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#listItem","position":3,"name":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?","previousItem":{"@type":"ListItem","@id":"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/#listItem","name":"Alzheimer"}}]},{"@type":"Person","@id":"https:\/\/o-force.info\/index.php\/author\/3d94259663e4aa3a8a6ec49c5878263511996f44\/#author","url":"https:\/\/o-force.info\/index.php\/author\/3d94259663e4aa3a8a6ec49c5878263511996f44\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/8d951f253ec39500cd05ce5b251166e5f9ad4df75285b9277068441bbf1fb7b2?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#webpage","url":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/","name":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd","description":"The short peptide we are developing (JAL-TA9) is expect","inLanguage":"ja","isPartOf":{"@id":"https:\/\/o-force.info\/#website"},"breadcrumb":{"@id":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/#breadcrumblist"},"author":{"@id":"https:\/\/o-force.info\/index.php\/author\/3d94259663e4aa3a8a6ec49c5878263511996f44\/#author"},"creator":{"@id":"https:\/\/o-force.info\/index.php\/author\/3d94259663e4aa3a8a6ec49c5878263511996f44\/#author"},"datePublished":"2023-12-23T06:25:43+00:00","dateModified":"2025-02-02T11:02:25+00:00"},{"@type":"WebSite","@id":"https:\/\/o-force.info\/#website","url":"https:\/\/o-force.info\/","name":"O-Force Co., Ltd","description":"\u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3092\u76ee\u6307\u3059\u4f1a\u793e","inLanguage":"ja","publisher":{"@id":"https:\/\/o-force.info\/#person"}}]},"og:locale":"ja_JP","og:site_name":"O-Force Co., Ltd - \u30a2\u30eb\u30c4\u30cf\u30a4\u30de\u30fc\u75c5\u6cbb\u7642\u85ac\u306e\u958b\u767a\u3092\u76ee\u6307\u3059\u4f1a\u793e","og:type":"article","og:title":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd","og:description":"The short peptide we are developing (JAL-TA9) is expect","og:url":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/","article:published_time":"2023-12-23T06:25:43+00:00","article:modified_time":"2025-02-02T11:02:25+00:00","twitter:card":"summary","twitter:title":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab? - O-Force Co., Ltd","twitter:description":"The short peptide we are developing (JAL-TA9) is expect"},"aioseo_meta_data":{"post_id":"1283","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-12-23 06:25:44","updated":"2025-06-25 05:32:37","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/o-force.info\" title=\"\u30db\u30fc\u30e0\">\u30db\u30fc\u30e0<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/\" title=\"Alzheimer\">Alzheimer<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"\u30db\u30fc\u30e0","link":"https:\/\/o-force.info"},{"label":"Alzheimer","link":"https:\/\/o-force.info\/index.php\/en\/category\/alzheimer\/"},{"label":"9\/25, 2023 Recanemab has been approved by the MHLW for the treatment of Alzheimer's disease; will O-Force's short peptide (JAL-TA9) in development be a safer and cheaper fundamental treatment beyond recanemab?","link":"https:\/\/o-force.info\/index.php\/en\/2023\/12\/23\/researech4\/"}],"veu_head_title_object":{"title":"","add_site_title":""},"_links":{"self":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/comments?post=1283"}],"version-history":[{"count":20,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283\/revisions"}],"predecessor-version":[{"id":2027,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/posts\/1283\/revisions\/2027"}],"wp:attachment":[{"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/media?parent=1283"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/categories?post=1283"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/o-force.info\/index.php\/wp-json\/wp\/v2\/tags?post=1283"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}